Can a pill turn back the clock? scientists test Anti-Aging drugs in seniors

NCT ID NCT06658093

Recruiting now Disease control Sponsor: The University of Texas Health Science Center at San Antonio Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study is testing two drugs, rapamycin and everolimus, in 194 healthy adults aged 65 to 90. The goal is to find a safe dose and timing that can reduce a key aging signal in cells to levels seen in younger people. The researchers also want to see if the best dose differs between men and women.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rapamycin (sirolimus) and everolimus (Afinitor), both mTOR inhibitors
What this could lead to: If successful, this study could identify safe doses of these drugs that mimic the cellular activity of younger people, potentially pointing toward a way to slow aging and reduce age-related diseases.
What could go wrong: This is a very early, exploratory trial focused on dosing and safety, not on proving that the drugs actually slow aging in humans. The results may not translate to real-world benefits, and mTOR inhibitors have known side effects like immune suppression and mouth sores.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGING

Contacts and locations

Locations

The University of Texas Health Science Center at San Antonio
RECRUITING

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.